Reckitt ‘Relief Rally’ Leads Shares Higher as Firm Cleared Over Baby Formula Case

For investors who have faced nothing but uncertainty over the case, today’s rally will come as welcome news

Christopher Johnson 1 November, 2024 | 11:00AM
Facebook Twitter LinkedIn

Illustration collage of clock with graphical elements pointing up and down

Shares in Reckitt RKT leapt by over 10% this morning after the hygiene, health and nutrition group was cleared of liability in a case against its baby formula.

A court in Missouri rejected the claim that the baby formula, made by Reckitt’s Mead Johnson division in collaboration with the medical company Abbott ABT, led to necrotizing enterocolitis—an inflation of the bowel that requires invasive surgery.

Plaintiffs argued that both Reckitt and Abbott had knowledge of the risks the baby formula posed but withheld information.

This case is related to one infant, although 1,000 similar cases are pending against the two companies.

At the time of writing, Reckitt shares are currently up 8.57%.

Key Morningstar Metrics for Reckitt Benckiser Group RKT

Economic Moat: Wide
Fair Value Estimate: £65.00.
Morningstar Rating: 4 stars
Sector: Consumer Defensive
Morningstar Uncertainty Rating: Medium

Russ Mould, investment director at AJ Bell described Reckitt’s share price jump as a “relief rally” off the back of the Missouri ruling.

“There has been nothing but bad news on this front for Reckitt for some time so it’s not a surprise this chink of light has been seized upon by investors in a positive way,” he said.

“There are still plenty of outstanding cases so this issue will not go away for Reckitt overnight, but it certainly represents a crumb of comfort for long-suffering shareholders.

“An eventual resolution of this issue could be a precursor to selling the Mead Johnson business, which has been nothing short of a disaster for Reckitt since it was acquired for $16.6 billion in 2017.”

Reckitt is already planning to offload some of its consumer households and goods brands with the sales of products like air freshener Airwick and Cillit Bang cleaner.

In July, Reckitt also announced plans to reshape its business to focus on a portfolio of power bands ranging from Gaviscon to Nurofen.

The company’s stock is currently trading at £51.02 per share, below Morningstar’s Fair Value Estimate of £65.


The author or authors do not own shares in any securities mentioned in this article. Find out about Morningstar's editorial policies.

The information contained within is for educational and informational purposes ONLY. It is not intended nor should it be considered an invitation or inducement to buy or sell a security or securities noted within nor should it be viewed as a communication intended to persuade or incite you to buy or sell security or securities noted within. Any commentary provided is the opinion of the author and should not be considered a personalised recommendation. The information contained within should not be a person's sole basis for making an investment decision. Please contact your financial professional before making an investment decision.

Facebook Twitter LinkedIn

Securities Mentioned in Article

Security NamePriceChange (%)Morningstar
Rating
Abbott Laboratories113.42 USD-0.71Rating
Reckitt Benckiser Group PLC4,820.00 GBX0.25Rating

About Author

Christopher Johnson  is data journalist at Morningstar

© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures